Goldman Sachs’s Chembio diagnostics, Inc. CEMI Stock Holding History

Goldman Sachs’s Portfolio CEMI Stock Details CEMI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-92,168	Closed	-$105K	–	7214
2021 Q4	$105K	Buy	+92,168	New	+$188K	﹤0.01%	6117
2021 Q3	–	Sell	-80,184	Closed	-$238K	–	6778
2021 Q2	$238K	Buy	80,184 +68,981	+616%	+$240K	﹤0.01%	5658
2021 Q1	$39K	Sell	11,203 -188,844	-94%	-$1.05M	﹤0.01%	5971
2020 Q4	$950K	Buy	+200,047	New	+$1.03M	﹤0.01%	4227
2020 Q3	–	Sell	-32,871	Closed	-$107K	–	5697
2020 Q2	$107K	Buy	+32,871	New	+$312K	﹤0.01%	4976
2017 Q3	–	Sell	-24,881	Closed	-$151K	–	7137
2017 Q2	$151K	Buy	+24,881	New	+$155K	﹤0.01%	5947
2015 Q4	–	Sell	-10,456	Closed	-$42K	–	7686
2015 Q3	$42K	Sell	10,456 -2,078	-17%	-$9.4K	﹤0.01%	6855
2015 Q2	$62K	Buy	+12,534	New	+$57.9K	﹤0.01%	6809
2015 Q1	–	Sell	-10,965	Closed	-$43K	–	7618
2014 Q4	$43K	Buy	+10,965	New	+$45.4K	﹤0.01%	6853

Other funds holding CEMI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EGM

Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs's CEMI Position: Q1 2022 in Review

Goldman Sachs sold out of Chembio diagnostics, Inc. (CEMI) in Q1 2022, closing a stake of 92,168 shares — an estimated $105K sold.

Goldman Sachs first reported a position in CEMI in Q4 2014 and held it in 9 quarters. The position peaked at $950K in Q4 2020. 36 funds tracked by Wall St. Rank hold CEMI as of Q1 2022.

Goldman Sachs reported no remaining Chembio diagnostics, Inc. position as of Q1 2022 after selling out during the quarter.
Goldman Sachs sold 92,168 Chembio diagnostics, Inc. shares in Q1 2022, an estimated $105K.
Goldman Sachs first reported a position in Chembio diagnostics, Inc. in Q4 2014 and held it in 9 quarters.
Goldman Sachs's Chembio diagnostics, Inc. position peaked at $950K in Q4 2020.
36 funds tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.